Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and thank you for joining Zevra's first quarter 2025 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today. The host for today's call is Nicole Oshner, Zevra's vice president. Please go ahead. Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of first quarter financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with sever's business forward-looking statements are not promises or guarantees and are inherently subject to risks uncertainties and other important factors that may lead actual results differing materially from projections made These forward-looking statements should be evaluated together with the cautionary statements contained in the risk factors section in our most recently quarterly report on Form 10-Q, annual report on Form 10-K, and our other filings with the SEC. I am pleased to welcome ZEVR's management team members participating in today's call. Neal McFarlane, Zevers President and Chief Executive Officer, LaDwayne Clifton, our Chief Financial Officer, and Josh Schaefer, our Chief Commercial Officer. Our Chief Medical Officer, Adrian Cortell, will also be available for today's question and answer session. Now, it's my pleasure to turn the call over to...